Upregulated serum miR-128-3p in progressive and relapse-free multiple sclerosis patients.
biomarker
microRNA
multiple sclerosis
Journal
Acta neurologica Scandinavica
ISSN: 1600-0404
Titre abrégé: Acta Neurol Scand
Pays: Denmark
ID NLM: 0370336
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
16
01
2020
revised:
05
05
2020
accepted:
14
05
2020
pubmed:
21
5
2020
medline:
13
1
2021
entrez:
21
5
2020
Statut:
ppublish
Résumé
Circulating microRNAs have emerged as novel multiple sclerosis (MS) biomarkers. To assess the association between candidate miR expression in serum samples of patients with MS and the disease course. Serum levels of ten microRNAs (ie, miR-199, miR-128-3p, miR-20a-5p, miR-27a-3p, miR-15b-5p, miR-325, miR-92a1-5p, miR-223-5p, miR-22-5p, and miR-23a-5p) were measured in 74 MS cases and 17 non-MS controls consecutively enrolled at Verona University Hospital. The association of microRNA expression with patients' clinical and MRI features was analyzed. Candidate microRNAs were detected by real-time PCR and expressed as ratio of each microRNA level to a normalizer. Serum miR-128-3p levels were higher in progressive than relapsing MS (median ratio 2.86 vs 0.73, P = .036). In addition, miR-128-3p was upregulated in patients without relapses after sample collection compared to cases who relapsed (1.64 vs 0.82; P = .014). miR-128-3p levels and relapse rate were inversely correlated (r = -.44, P = .008). Serum levels of mir-128-3p could be related to biological mechanisms underlying MS activity and progression.
Sections du résumé
BACKGROUND
BACKGROUND
Circulating microRNAs have emerged as novel multiple sclerosis (MS) biomarkers.
AIMS
OBJECTIVE
To assess the association between candidate miR expression in serum samples of patients with MS and the disease course.
METHODS
METHODS
Serum levels of ten microRNAs (ie, miR-199, miR-128-3p, miR-20a-5p, miR-27a-3p, miR-15b-5p, miR-325, miR-92a1-5p, miR-223-5p, miR-22-5p, and miR-23a-5p) were measured in 74 MS cases and 17 non-MS controls consecutively enrolled at Verona University Hospital. The association of microRNA expression with patients' clinical and MRI features was analyzed. Candidate microRNAs were detected by real-time PCR and expressed as ratio of each microRNA level to a normalizer.
RESULTS
RESULTS
Serum miR-128-3p levels were higher in progressive than relapsing MS (median ratio 2.86 vs 0.73, P = .036). In addition, miR-128-3p was upregulated in patients without relapses after sample collection compared to cases who relapsed (1.64 vs 0.82; P = .014). miR-128-3p levels and relapse rate were inversely correlated (r = -.44, P = .008).
CONCLUSIONS
CONCLUSIONS
Serum levels of mir-128-3p could be related to biological mechanisms underlying MS activity and progression.
Substances chimiques
Biomarkers
0
Circulating MicroRNA
0
MIRN128 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
511-516Subventions
Organisme : Fondazione Cassa di Risparmio di Verona Vicenza Belluno e Ancona
ID : NA
Organisme : Merck
ID : NA
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Curtale G. MiRNAs at the crossroads between innate immunity and cancer: focus on macrophages. Cells. 2018;7(2):12.
Huang Q, Xiao B, Ma X, et al. MicroRNAs associated with the pathogenesis of multiple sclerosis. J Neuroimmunol. 2016;295-296:148-161.
Kacperska MJ, Jastrzebski K, Tomasik B, Walenczak J, Konarska-Krol M, Glabinski A. Selected extracellular microRNA as potential biomarkers of multiple sclerosis activity-preliminary study. J Mol Neurosci. 2015;56(1):154-163.
Fenoglio C, Ridolfi E, Cantoni C, et al. Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. Mult. Scler. 2013;19:1938-1942.
Keller A, Leidinger P, Lange J, et al. Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PLoS One. 2009;4:e7440.
Regev K, Paul A, Healy B, et al. Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e267.
Khoury S, Ajuyah P, Tran N. Isolation of small noncoding RNAs from human serum. J Vis Exp. 2014;88:e51443.
Guerau-de-Arellano M, Smith KM, Godlewski J, et al. Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell- mediated autoimmunity. Brain. 2011;134(Pt 12):3578-3589.
Vistbakka J, Elovaara I, Lehtimaki T, Hagman S. Circulating microRNAs as biomarkers in progressive multiple sclerosis. Mult Scler. 2017;23:403-412.
Vistbakka J, Sumelahti M-L, Lehtimäki T, Elovaara I, Hagman S. Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients. Acta Neurol Scand. 2018;138:130-136.
Heegaard NHH, Carlsen AL, Skovgaard K, Heegaard PMH. Circulating extracellular microRNA in systemic autoimmunity. Exp Suppl. 2015;106:171-195.
Zhang Z, Han Y, Sun G, Liu X, Jia X, Yu X. MicroRNA-325-3p inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma by down-regulation of aquaporin 5. Cell Mol Biol Lett. 2019;12(24):13.